๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Tailoring antiviral therapy in hepatitis C

โœ Scribed by Gary L. Davis

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
53 KB
Volume
43
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Hepatitis C virus kinetics in chimeric m
Hepatitis C virus kinetics in chimeric mice during antiviral therapy
โœ Harel Dahari; Alan S. Perelson ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 63 KB ๐Ÿ‘ 1 views

Our data support the findings of Wieckowska et al. 2 in demonstrating that measuring serum CK-18 fragments level could potentially be used as a noninvasive diagnostic test to predict the severity of NAFLD; however, before the liver biopsy is abandoned altogether, verification of the noninvasive diag

Triphasic decline of hepatitis C virus R
Triphasic decline of hepatitis C virus RNA during antiviral therapy
โœ Harel Dahari; Ruy M. Ribeiro; Alan S. Perelson ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 237 KB ๐Ÿ‘ 1 views

When patients chronically infected with hepatitis C virus (HCV) are placed on antiviral therapy with pegylated interferon (IFN)-โฃ or IFN-โฃ plus ribavirin (RBV), HCV RNA generally declines in a biphasic manner. However, a triphasic decline has been reported in a subset of patients. A triphasic declin

Clearance kinetics of hepatitis C virus
Clearance kinetics of hepatitis C virus under different antiviral therapies
โœ Francesco Torre; Rosella Giusto; Alessandro Grasso; Renata Brizzolara; Nadia Cam ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 102 KB ๐Ÿ‘ 1 views

## Abstract Interferon alpha (IFN) has been the standard treatment for hepatitis C virus (HCV) infection. Using the kinetic curves of viral clearance, this study compared three treatment regimes based on IFN alone or in combination with Amantadine or Ribavirin to determine the mechanisms of action

Public health impact of antiviral therap
Public health impact of antiviral therapy for hepatitis C in the United States
โœ Michael L. Volk; Rachel Tocco; Sameer Saini; Anna S.F. Lok ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 273 KB ๐Ÿ‘ 1 views

Despite dramatic improvements in antiviral therapy for hepatitis C, there is reason to believe that the uptake of antiviral therapy remains limited. The aims of this study were to determine the number of patients being treated with antiviral therapy in the U.S., to estimate the public health impact